
Eden Research plc offers sustainable solutions for crop protection, animal health, and consumer products in the United Kingdom and rest of Europe. The company provides crop protection products for foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatment applications. It also offers animal health products, such as companion animal, bio-control, parasite treatments, and insect spray products. In addition, the company provides human health products comprising head-lice treatment products, fragrances, deodorants, wound-care products, food flavorings, odor neutralizers, and active ingredient supply/delivery products. The company was incorporated in 1995 and is headquartered in Abingdon, the United Kingdom.
Eden Research plc trades as EDNSF on OTC. The company is classified in Basic Materials / Agricultural Inputs and reports in USD.
The current profile places the business in Agricultural Inputs. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows $4.30M of revenue and -$1.91M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
Eden Research plc can be compared against peers such as Benjamin Hill Mining Corp., Golden Rapture Mining Corporation, Harvest Minerals Limited, First Uranium Resources Ltd., Kenongwo Group US, Inc., Nighthawk Gold Corp..
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of $18.08M, beta of 1.82, and return on equity of -16.1%.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
EDNSF currently shows total debt of $168,732 and beta of 1.82. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
No recent SEC-style filings are available for this symbol yet.
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.edenresearch.com
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.